(12) **Translation of European patent specification**

(11) **NO/EP 3494960 B1**

NORWAY

(19) NO

(51) Int Cl.
A61K 9/00 (2006.01)
A61K 9/06 (2006.01)
A61K 31/131 (2006.01)
A61K 47/10 (2017.01)
A61P 17/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.01.18
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.11.25
(86)	European Application Nr.	18214529.2
(86)	European Filing Date	2009.03.11
(87)	The European Application's Publication Date	2019.06.12
(30)	Priority	2008.03.27, US, 3984008 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(62)	Divided application	EP2273876, 2009.03.11
(73)	Proprietor	Helsinn Healthcare SA, Via Pian Scairolo 9, 6912 Lugano-Pazzallo, Sveits
(72)	Inventor	ALONSO, Robert, 554 Dannaker Lane, Wayne, PA 19087, USA WALKER, Barry R., 714 Pennstone Rd, Bryn Mawr, PA 19010, USA CROOKS, Peter A., 22 Ridgefield Cove, Little Rock, AR 72223, USA
(74)	Agent or Attorney	PROTECTOR IP AS, Pilestredet 33, 0166 OSLO, Norge

(54) Title **STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME**

(56) References Cited: US-A1- 2006 205 694

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Krav

1. Sammensetning bestående av:
0,02 masse-% mekloretamin hydroklorid;
2,00 masse-% hydroksypropyl cellulose;
0,01 masse-% edetat dinatrium dihydrat;
0,05 masse-% racemisk mentol;
0,01 masse-% butylert hydroksytoluen;
49,91 masse-% 2-/2-etoksy-etoksy) etanol;
15,27 masse-% isopropyl alkohol;
17,57 masse-% propylen glykol;
11,33 masse-% glyserin;
3,65 masse-% racemisk melkesyre; og
0,18 masse-% natrium klorid,
for bruk som et medikament.

2. En sammensetning i henhold til krav 1 for bruk ved topisk behandling av en hudlidelse.

3. En sammensetning for bruk i henhold til kav 2, hvor hudlidelsen er valgt fra gruppen bestående av psoriasis, eksem, solar keratose, lupus, sarkoidose, alopeci, kutanøs T-celle lymfom (det vil si mykose fungoider), lymforetikulær neoplasi, pleurale og peritonale effusjoner, kutan B-celle lymfom, pseudolymfomaer i huden, skjelettcelle karsinom, basalcelle karsinom, bronkogen karsinom, malignt melanom, lymfosarkom, kronisk lymfocytt leukemi, polycytemi vera, lymfomatoid papulose, Mucha-Habbermanns lidelse, vitiligo, og kombinasjoner derav.

4. En sammensetning for bruk i henhold til krav 3, hvor hudlidelsen er vitiligo.

5. En sammensetning i henhold til krav 3, hvor hudlidelsen er kutan T-celle lymfom (det vil si mykose fungoider).